BR0307629A - Métodos e composições para tratar condições hiperproliferativas - Google Patents

Métodos e composições para tratar condições hiperproliferativas

Info

Publication number
BR0307629A
BR0307629A BR0307629-6A BR0307629A BR0307629A BR 0307629 A BR0307629 A BR 0307629A BR 0307629 A BR0307629 A BR 0307629A BR 0307629 A BR0307629 A BR 0307629A
Authority
BR
Brazil
Prior art keywords
combination
treating hyperproliferative
compositions
methods
relates
Prior art date
Application number
BR0307629-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Dean Stiles
Carlos Garcia-Echeverria
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR0307629A publication Critical patent/BR0307629A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0307629-6A 2002-02-14 2003-02-14 Métodos e composições para tratar condições hiperproliferativas BR0307629A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35691202P 2002-02-14 2002-02-14
PCT/EP2003/001507 WO2003068265A1 (en) 2002-02-14 2003-02-14 Methods and compositions for treating hyperproliferative conditions

Publications (1)

Publication Number Publication Date
BR0307629A true BR0307629A (pt) 2005-01-11

Family

ID=27734705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307629-6A BR0307629A (pt) 2002-02-14 2003-02-14 Métodos e composições para tratar condições hiperproliferativas

Country Status (11)

Country Link
EP (1) EP1476192B1 (https=)
JP (1) JP5053503B2 (https=)
CN (1) CN100591355C (https=)
AT (1) ATE360442T1 (https=)
AU (1) AU2003205768A1 (https=)
BR (1) BR0307629A (https=)
CA (1) CA2476000A1 (https=)
DE (1) DE60313434T2 (https=)
ES (1) ES2283744T3 (https=)
PT (1) PT1476192E (https=)
WO (1) WO2003068265A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
CN1117097C (zh) * 1998-05-29 2003-08-06 北京金赛狮生物制药技术开发有限责任公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Also Published As

Publication number Publication date
DE60313434T2 (de) 2008-01-10
CN100591355C (zh) 2010-02-24
CA2476000A1 (en) 2003-08-21
PT1476192E (pt) 2007-07-26
DE60313434D1 (de) 2007-06-06
JP2005517040A (ja) 2005-06-09
ES2283744T3 (es) 2007-11-01
WO2003068265A1 (en) 2003-08-21
CN1630534A (zh) 2005-06-22
JP5053503B2 (ja) 2012-10-17
ATE360442T1 (de) 2007-05-15
EP1476192B1 (en) 2007-04-25
AU2003205768A1 (en) 2003-09-04
EP1476192A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
WO2009118662A3 (en) Methods and compositions for treating bone loss
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
AR023130A1 (es) Composiciones para promover el crecimiento
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
EP2666472A3 (en) Uses and compositions for treatment of psoriatic arthritis
TN2009000213A1 (en) Combination
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
TW200806293A (en) Methods of treatment with CETP inhibitors
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.